These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17323508)

  • 21. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
    Gupta SK
    AIDS Read; 2009; 19(6):246. PubMed ID: 19642244
    [No Abstract]   [Full Text] [Related]  

  • 22. [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir].
    de la Prada FJ; Prados AM; Tugores A; Uriol M; Saus C; Morey A
    Nefrologia; 2006; 26(5):626-30. PubMed ID: 17117909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
    Nurutdinova D; Onen NF; Hayes E; Mondy K; Overton ET
    Ann Pharmacother; 2008 Nov; 42(11):1581-5. PubMed ID: 18957630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature.
    Quimby D; Brito MO
    AIDS Read; 2005 Jul; 15(7):357-64. PubMed ID: 16044577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate.
    Shepp DH; Curtis S; Rooney JF
    AIDS; 2007 Jul; 21(11):1479-81. PubMed ID: 17589195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.
    Kearney BP; Sayre JR; Flaherty JF; Chen SS; Kaul S; Cheng AK
    J Clin Pharmacol; 2005 Dec; 45(12):1360-7. PubMed ID: 16291710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy.
    Buchacz K; Brooks JT; Tong T; Moorman AC; Baker RK; Holmberg SD; Greenberg A;
    HIV Med; 2006 Oct; 7(7):451-6. PubMed ID: 16925731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases.
    Lockhart SM; Rathbun RC; Stephens JR; Baker DL; Drevets DA; Greenfield RA; Salvaggio MR; Vincent S
    AIDS; 2007 Jun; 21(10):1370-3. PubMed ID: 17545718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
    Cicconi P; Bongiovanni M; Melzi S; Tordato F; d'Arminio Monforte A; Bini T
    Int J Antimicrob Agents; 2004 Sep; 24(3):284-5. PubMed ID: 15325433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy.
    Parsonage MJ; Wilkins EG; Snowden N; Issa BG; Savage MW
    HIV Med; 2005 Sep; 6(5):341-6. PubMed ID: 16156882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir for the treatment of hepatitis B virus.
    Jenh AM; Thio CL; Pham PA
    Pharmacotherapy; 2009 Oct; 29(10):1212-27. PubMed ID: 19792994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tenofovir: what have over 1 million years of patient experience taught us?
    Pozniak A
    Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
    Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
    Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
    Ter Heine R; Huitema AD; Jansen RS; Smits PH; van Gorp EC; Wagenaar JF; Beijnen JH; Mulder JW
    Antivir Ther; 2009; 14(2):299-301. PubMed ID: 19430105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tenofovir and renal toxicity.
    AIDS Patient Care STDS; 2004 Oct; 18(10):615-6. PubMed ID: 15633256
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV therapy may be given safely in resource-limited settings without routine laboratory monitoring.
    AIDS Patient Care STDS; 2009 Aug; 23(8):680-1. PubMed ID: 19694040
    [No Abstract]   [Full Text] [Related]  

  • 37. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
    Kakuda TN; Anderson PL; Becker SL
    AIDS; 2004 Dec; 18(18):2442-4. PubMed ID: 15622326
    [No Abstract]   [Full Text] [Related]  

  • 38. Tenofovir: FDA hearing October 3, public comment deadlines September 26.
    James JS
    AIDS Treat News; 2001 Aug; (370):3-4. PubMed ID: 11570163
    [No Abstract]   [Full Text] [Related]  

  • 39. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
    Soler-Palacín P; Melendo S; Noguera-Julian A; Fortuny C; Navarro ML; Mellado MJ; Garcia L; Uriona S; Martín-Nalda A; Figueras C
    AIDS; 2011 Jan; 25(2):171-6. PubMed ID: 21076275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.
    Rodríguez-Nóvoa S; Labarga P; D'avolio A; Barreiro P; Albalate M; Vispo E; Solera C; Siccardi M; Bonora S; Di Perri G; Soriano V
    AIDS; 2010 Apr; 24(7):1064-6. PubMed ID: 20299966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.